David G. Watumull, CEO of Cardax, was on Hawaii News Now Sunrise to discuss Cardax's new clinical trial studying the effects of astaxanthin on cardio-inflammatory health.
Read More
Cardax CEO, David G. Watumull, was featured Friday, September 21, 2018, on the business television and radio show, The Big Biz Show. The show is simulcast on television and radio and is available throughout the U.S. and in other countries on multiple outlets. Cardax made no payments of any kind to appear on the show.
Read More
False and baseless assertions about our dietary supplement ZanthoSyn® have recently been in the news, so we want to set the record straight about its anti-inflammatory health benefits, safety, and regulatory status. Promoting the health and well-being of our consumers is and always will be our paramount focus at Cardax. It is in this spirit that we wanted to share with you the following information about this pure and highly absorbed form of astaxanthin that...
Read More
By Gilbert Rishton, Ph.D., Cardax Chief Science Officer I accepted my position at Cardax as a seasoned veteran of the pharmaceutical industry. And, while my industry experience was indeed marked with satisfying projects, and even a successful drug launch with my former colleagues at Amgen, my most profound impression of modern drug development is in its epic failures. Particularly, the industry has failed to deliver the innovative new drugs that were to address society’s most…
By David G. Watumull, Cardax President and CEO It is my distinct pleasure to welcome you to the first Cardax blog post. Our goal is to provide timely and interactive communication for investors and others interested in our Company. In addition to formal press releases and SEC filings we make available through other channels, we hope to offer personal perspective on several relevant areas, including the Company’s progress, capital markets, and relevant developments in the…